Cross-License Agreement Boosts Cardiovascular Medical Device Development

Strategic Insights -

CorMatrix Cardiovascular and Cook Biotech have partnered to facilitate the development of cutting-edge cardiovascular medical devices using proprietary biomaterials. The cross-license agreement enables the Atlanta-based tissue-engineering company to leverage Cook's expertise in manufacturing extracellular matrix (ECM) biomaterials, expanding its product pipeline to treat cardiac tissue diseases. Potential applications include cardiac patch repairs for adult and pediatric heart defects, myocardial grafts for congestive heart failure, and stimulation of myocardial angiogenesis. This collaboration is expected to accelerate the development of innovative medical devices.

Key Takeaways:

  • CorMatrix Cardiovascular and Cook Biotech have entered into a cross-license agreement to promote the development of cardiovascular medical devices.
  • The partnership combines CorMatrix's extracellular matrix materials with Cook Biotech's widely-used biomaterials for tissue-engineered medical products.
  • CorMatrix plans to develop products for the repair of heart defects, including cardiac patches for adult and pediatric patients, as well as myocardial grafts and angiogenesis stimulation treatments.
  • The partnership aims to fully utilize Cook Biotech's ECM tissue scaffolds for new products in cardiovascular applications.
  • The agreement will accelerate the development of innovative medical devices for the treatment of cardiac tissue diseases.
  • Dennis Abbott, director of business development at Cook Biotech, and Beecher Lewis, president and COO of CorMatrix, have expressed enthusiasm about the partnership and its potential to enhance their respective company's product pipelines.
  • Cook Biotech's experience in manufacturing well-characterized ECM biomaterials is expected to greatly enhance CorMatrix's development efforts.

Statistics:

  • The partnership combines the expertise of two companies in the field of cardiovascular medical devices.
  • CorMatrix plans to develop products for the repair of heart defects, including cardiac patches for adult and pediatric patients.
  • Myocardial grafts and angiogenesis stimulation treatments are potential applications of the partnership.
  • Cook Biotech's experience in manufacturing ECM biomaterials will be integral to the development of new products.
  • The agreement will accelerate the development of innovative medical devices.

Sources:

  • "Cook Biotech and CorMatrix Cardiovascular have announced a recently established cross-license agreement." (Source: Wireless News, http://www.10meters.com)
  • "CorMatrix, an Atlanta, Ga., tissue-engineering and medical device manufacturing company, will develop products for repair of the heart." (Source: Wireless News, http://www.10meters.com)
  • "We are excited about the addition of Cook's widely-used biomaterials to our existing technology platform..." (Beecher Lewis, president and COO of CorMatrix) (Source: Wireless News, http://www.10meters.com)
  • "Cook Biotech is actively working to provide a selection of well characterized ECM biomaterials for use in tissue-engineered medical products." (Dennis Abbott, director of business development at Cook Biotech) (Source: Wireless News, http://www.10meters.com)